A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Article in Clinical Cancer Research (February 2024)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Article in Clinical Cancer Research (February 2024)
Article in Bioconjugate Chemistry (November 2023)
Article in Cancer Immunology, Immunotherapy (August 2023)